US3174901A
(en)
|
1963-01-31 |
1965-03-23 |
Jan Marcel Didier Aron Samuel |
Process for the oral treatment of diabetes
|
NL167151C
(nl)
|
1971-04-09 |
1981-11-16 |
Acf Chemiefarma Nv |
Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen.
|
DE2758025A1
(de)
|
1977-12-24 |
1979-07-12 |
Bayer Ag |
Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
|
NO154918C
(no)
|
1977-08-27 |
1987-01-14 |
Bayer Ag |
Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
|
DE2951135A1
(de)
|
1979-12-19 |
1981-06-25 |
Hoechst Ag, 6230 Frankfurt |
Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
|
JPS5639056A
(en)
|
1980-07-16 |
1981-04-14 |
Kanebo Ltd |
Preparation of n,n,n',n'-tetraacylated nucleus halogenated aromatic diamine
|
JPS58164502A
(ja)
|
1982-03-26 |
1983-09-29 |
Chugai Pharmaceut Co Ltd |
除草用組成物
|
US4602023A
(en)
|
1985-06-03 |
1986-07-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
US4786755A
(en)
|
1985-06-03 |
1988-11-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
US4786023A
(en)
|
1987-08-19 |
1988-11-22 |
Harris Leverett D |
Drafting implement holder
|
US6297273B1
(en)
|
1996-04-02 |
2001-10-02 |
Mars, Inc. |
Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
|
JPH1085502A
(ja)
|
1996-09-19 |
1998-04-07 |
Konica Corp |
晶析方法
|
WO1998031697A1
(en)
|
1997-01-15 |
1998-07-23 |
Sankyo Company, Limited |
Aryl c-glycoside compounds and sulfated esters thereof
|
JPH11124392A
(ja)
|
1997-10-21 |
1999-05-11 |
Sankyo Co Ltd |
C−グリコシル化されたアリールスズ化合物
|
DE19846314A1
(de)
|
1998-10-08 |
2000-04-13 |
Basf Ag |
Polyolefinnanocomposite
|
US6613806B1
(en)
|
1999-01-29 |
2003-09-02 |
Basf Corporation |
Enhancement of the efficacy of benzoylbenzenes
|
EP1213296B1
(en)
|
1999-08-31 |
2004-04-14 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
|
PH12000002657B1
(en)
|
1999-10-12 |
2006-02-21 |
Bristol Myers Squibb Co |
C-aryl glucoside SGLT2 inhibitors
|
US6515117B2
(en)
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6498193B2
(en)
|
1999-12-22 |
2002-12-24 |
Trustees Of Dartmouth College |
Treatment for complications of type 2 diabetes
|
US6627611B2
(en)
|
2000-02-02 |
2003-09-30 |
Kotobuki Pharmaceutical Co Ltd |
C-glycosides and preparation of thereof as antidiabetic agents
|
JP4456768B2
(ja)
|
2000-02-02 |
2010-04-28 |
壽製薬株式会社 |
C−配糖体を含有する薬剤
|
SK287183B6
(sk)
|
2000-03-17 |
2010-02-08 |
Kissei Pharmaceutical Co., Ltd. |
Glukopyranozyloxybenzylbenzenový derivát, farmaceutická kompozícia s jeho obsahom, ich použitie a medziprodukt
|
US6683056B2
(en)
|
2000-03-30 |
2004-01-27 |
Bristol-Myers Squibb Company |
O-aryl glucoside SGLT2 inhibitors and method
|
UA73606C2
(en)
|
2000-09-29 |
2005-08-15 |
Kissei Pharmaceutical |
Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing them
|
US7053060B2
(en)
|
2000-11-30 |
2006-05-30 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
|
TWI255817B
(en)
|
2001-02-14 |
2006-06-01 |
Kissei Pharmaceutical |
Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
|
EP1360172A1
(en)
|
2001-02-15 |
2003-11-12 |
Pfizer Products Inc. |
Ppar agonists
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
JP3698067B2
(ja)
|
2001-03-30 |
2005-09-21 |
Jsr株式会社 |
電子吸引性基および電子供与性基を有するモノマー、それを用いた共重合体、ならびにプロトン伝導膜
|
JP2004536047A
(ja)
|
2001-04-11 |
2004-12-02 |
ブリストル−マイヤーズ スクイブ カンパニー |
糖尿病処置用c−アリールグルコシドのアミノ酸複合体および方法
|
DE10139416A1
(de)
|
2001-08-17 |
2003-03-06 |
Aventis Pharma Gmbh |
Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US20030087843A1
(en)
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
WO2003031458A1
(en)
|
2001-10-12 |
2003-04-17 |
Dana-Farber Cancer Institute |
Methods for synthesis of diarylmethanes
|
AU2003203143B2
(en)
|
2002-02-01 |
2009-05-14 |
High Point Pharmaceuticals, Llc |
Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
DE10231370B4
(de)
|
2002-07-11 |
2006-04-06 |
Sanofi-Aventis Deutschland Gmbh |
Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
TWI254635B
(en)
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
JP4540475B2
(ja)
|
2002-08-08 |
2010-09-08 |
キッセイ薬品工業株式会社 |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
PT1532149E
(pt)
|
2002-08-21 |
2010-02-17 |
Boehringer Ingelheim Pharma |
8-[3-amino-piperidinil-1-il]-xantinas, sua preparação e sua utilização como produto farmacêutico
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
MY136173A
(en)
|
2002-11-20 |
2008-08-29 |
Japan Tobacco Inc |
4-oxoquinoline compound and use thereof as hiv integrase inhibitor
|
JP3567162B1
(ja)
|
2002-11-20 |
2004-09-22 |
日本たばこ産業株式会社 |
4−オキソキノリン化合物及びそのhivインテグラーゼ阻害剤としての利用
|
JP4651934B2
(ja)
|
2002-12-04 |
2011-03-16 |
キッセイ薬品工業株式会社 |
ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
|
DE10258008B4
(de)
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
BR0317929A
(pt)
|
2003-01-03 |
2006-04-11 |
Bristol Myers Squibb Co |
métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
|
WO2004076470A2
(en)
|
2003-02-27 |
2004-09-10 |
Bristol-Myers Squibb Company |
A non-cryogenic process for forming glycosides
|
ES2363941T3
(es)
|
2003-03-14 |
2011-08-19 |
Astellas Pharma Inc. |
Derivados de c-glucósido para el tratamiento de diabetes.
|
US7674486B2
(en)
|
2003-05-14 |
2010-03-09 |
Indus Biotech Pvt. Ltd. |
Synergistic composition for the treatment of diabetes mellitus
|
AU2004252075A1
(en)
|
2003-06-03 |
2005-01-06 |
The Regents Of The University Of California |
Compositions and methods for treatment of disease with acetylated disaccharides
|
JP2004359630A
(ja)
|
2003-06-06 |
2004-12-24 |
Yamanouchi Pharmaceut Co Ltd |
ジフルオロジフェニルメタン誘導体及びその塩
|
NZ545304A
(en)
|
2003-08-01 |
2009-04-30 |
Mitsubishi Tanabe Pharma Corp |
Novel compounds having inhibitory activity against sodium-dependant transporter
|
WO2005011592A2
(en)
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted indazole-o-glucosides
|
TW200521131A
(en)
|
2003-08-01 |
2005-07-01 |
Janssen Pharmaceutica Nv |
Substituted fused heterocyclic c-glycosides
|
JP4131216B2
(ja)
|
2003-08-20 |
2008-08-13 |
Jsr株式会社 |
ポリアリーレンおよびその製造方法、ならびに高分子固体電解質およびプロトン伝導膜
|
EP1660509B1
(de)
|
2003-08-26 |
2009-02-04 |
Boehringer Ingelheim International GmbH |
Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US7375090B2
(en)
|
2003-08-26 |
2008-05-20 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
|
US20050085680A1
(en)
*
|
2003-10-21 |
2005-04-21 |
Joseph Auerbach |
Method for industrial decontamination
|
DE10361133A1
(de)
|
2003-12-22 |
2005-07-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Glucopyranosyloxy-substituierte Aromaten, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US7371732B2
(en)
|
2003-12-22 |
2008-05-13 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
|
US8058245B2
(en)
|
2004-03-04 |
2011-11-15 |
Kissei Pharmaceutical Co., Ltd. |
Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
|
RU2387663C2
(ru)
|
2004-03-04 |
2010-04-27 |
Киссеи Фармасьютикал Ко., Лтд. |
Конденсированные гетероциклические производные, содержащие их медицинские композиции и их медицинское применение
|
EP2360164A3
(de)
|
2004-03-16 |
2012-01-04 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE102004012676A1
(de)
*
|
2004-03-16 |
2005-10-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
CA2572149A1
(en)
|
2004-07-08 |
2006-01-19 |
Astellas Pharma Inc. |
Process for production of azulene derivatives and intermediates for the synthesis of the same
|
DE102004034690A1
(de)
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
EP1773800A1
(de)
|
2004-07-27 |
2007-04-18 |
Boehringer Ingelheim International GmbH |
D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
WO2006018150A1
(de)
|
2004-08-11 |
2006-02-23 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
MX2007003785A
(es)
|
2004-09-29 |
2007-07-12 |
Kissei Pharmaceutical |
Compuesto heterociclico nitrogenoso 1-(b-d-glicopiranosil)-3, composicion medicinal que contiene el mismo, y uso medicinal del mismo.
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
CA2587639A1
(en)
|
2004-12-16 |
2006-06-22 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
JP2006176443A
(ja)
|
2004-12-22 |
2006-07-06 |
Shionogi & Co Ltd |
メラニン凝集ホルモン受容体アンタゴニスト
|
GB0428180D0
(en)
|
2004-12-23 |
2005-01-26 |
Biopartners Ltd |
Combination therapy
|
GT200600008A
(es)
|
2005-01-18 |
2006-08-09 |
|
Formulacion de compresion directa y proceso
|
JP5264183B2
(ja)
|
2005-02-23 |
2013-08-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換((ヘテロ)アリールエチニル−ベンジル)−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体2(sglt2)インヒビターとしてのそれらの使用
|
JP5238492B2
(ja)
|
2005-04-15 |
2013-07-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sgltインヒビターとしてのグルコピラノシル置換(ヘテロアリールオキシ−ベンジル)−ベンゼン誘導体
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(en)
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
WO2007014894A2
(en)
|
2005-07-27 |
2007-02-08 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted ( (hetero) cycloalyklethynyl-benzyl) -benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
|
KR100780553B1
(ko)
|
2005-08-18 |
2007-11-29 |
한올제약주식회사 |
메트포르민 서방정 및 그의 제조방법
|
US7452872B2
(en)
|
2005-08-24 |
2008-11-18 |
Salix Pharmaceuticals, Inc. |
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
|
CA2620566A1
(en)
|
2005-08-30 |
2007-03-08 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
DE602006018961D1
(de)
|
2005-09-08 |
2011-01-27 |
Boehringer Ingelheim Pharma |
KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG
|
AR056195A1
(es)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
JOP20180109A1
(ar)
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
BRPI0617208A2
(pt)
|
2005-09-30 |
2011-07-19 |
Boehringer Ingelheim Vetmed |
preparação farmacêutica contendo meloxicam
|
JP2009531291A
(ja)
|
2006-02-15 |
2009-09-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
EP2269583B1
(en)
|
2006-06-16 |
2014-08-13 |
LEK Pharmaceuticals d.d. |
Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
|
PE20120542A1
(es)
|
2006-06-27 |
2012-05-14 |
Novartis Ag |
Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
|
TW200817424A
(en)
|
2006-08-04 |
2008-04-16 |
Daiichi Sankyo Co Ltd |
Benzylphenyl glucopyranoside derivatives
|
EP2054426A1
(en)
|
2006-08-15 |
2009-05-06 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
US20100227809A1
(en)
|
2006-08-17 |
2010-09-09 |
Wellstat Therapeutics Corporation |
Combination treatment for metabolic disorders
|
CA2664095A1
(en)
|
2006-09-21 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US8283326B2
(en)
|
2006-10-27 |
2012-10-09 |
Boehringer Ingelheim International Gmbh |
Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7879806B2
(en)
|
2006-11-06 |
2011-02-01 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture
|
MY157828A
(en)
|
2006-11-09 |
2016-07-29 |
Boehringer Ingelheim Int |
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
|
WO2008062273A2
(en)
|
2006-11-20 |
2008-05-29 |
Cadila Pharmaceuticals Limited |
Solid oral dosage form having antidiabetic drug combination
|
TW200838549A
(en)
|
2007-01-26 |
2008-10-01 |
Boehringer Ingelheim Int |
Methods for preventing and treating neurodegenerative disorders
|
EP2114937B1
(de)
|
2007-01-26 |
2011-06-29 |
Sanofi-Aventis |
Phenothiazin derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
|
US7879807B2
(en)
|
2007-02-21 |
2011-02-01 |
Boehringer Ingelheim International Gmbh |
Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
WO2008101938A1
(en)
|
2007-02-21 |
2008-08-28 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
|
ITFI20070042A1
(it)
|
2007-02-21 |
2008-08-22 |
Laboratori Guidotti Spa |
Formulazione farmaceutica e compressa comprendente detta formulazione.
|
TW200904454A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
WO2008144346A2
(en)
*
|
2007-05-18 |
2008-11-27 |
Bristol-Myers Squibb Company |
Crystal structures of sglt2 inhibitors and processes for their preparation
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
PE20090603A1
(es)
|
2007-08-16 |
2009-06-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
|
RS56990B1
(sr)
*
|
2007-09-10 |
2018-05-31 |
Janssen Pharmaceutica Nv |
Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
EP2249643A4
(en)
|
2008-02-05 |
2013-10-09 |
Merck Sharp & Dohme |
PHARMACEUTICAL COMPOSITIONS OF A METFORMIN AND DIPEPTIDYL PEPTIDASE-IV INHIBITOR ASSOCIATION
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
US20110015225A1
(en)
|
2008-04-01 |
2011-01-20 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
WO2010045656A2
(en)
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Novel sglt2 inhibitor dosage forms
|
WO2010092123A1
(en)
|
2009-02-13 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabete mellitus, impaired glucose tolerance or hyperglycemia
|
EP4327867A3
(en)
|
2009-02-13 |
2024-05-29 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
|
KR20160143897A
(ko)
|
2009-02-13 |
2016-12-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
Dpp-4 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
|
PT2395983T
(pt)
|
2009-02-13 |
2020-07-03 |
Boehringer Ingelheim Int |
Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
PL2601949T3
(pl)
|
2009-04-16 |
2015-04-30 |
Taisho Pharmaceutical Co Ltd |
Kompozycje farmaceutyczne z (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitolem oraz substancją zwiększającą wydzielanie insuliny
|
WO2010138535A1
(en)
|
2009-05-27 |
2010-12-02 |
Bristol-Myers Squibb Company |
Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
|
US20110077212A1
(en)
|
2009-09-25 |
2011-03-31 |
Theracos, Inc. |
Therapeutic uses of sglt2 inhibitors
|
BR112012007085B8
(pt)
|
2009-09-30 |
2021-05-25 |
Boehringer Ingelheim Int |
processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
|
AU2010303123B2
(en)
|
2009-09-30 |
2014-02-27 |
Boehringer Ingelheim International Gmbh |
Method for the preparation of a crystalline form of 1-chloro-4- (Beta-D-glucopyranos-1-yl)-2-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
MX2012005365A
(es)
|
2009-11-13 |
2012-05-29 |
Bristol Myers Squibb Co |
Formulaciones de tableta de liberacion inmediata.
|
WO2011120923A1
(en)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
MX2013002146A
(es)
|
2010-09-03 |
2013-04-03 |
Astrazeneca Uk Ltd |
Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
AU2012212448B9
(en)
|
2011-02-01 |
2015-06-25 |
Astrazeneca Uk Limited |
Pharmaceutical formulations including an amine compound
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
AU2012264736A1
(en)
|
2011-06-03 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
SGLT-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
DE102011109492A1
(de)
|
2011-08-04 |
2013-02-07 |
GM Global Technology Operations LLC (n. d. Gesetzen des Staates Delaware) |
Fahrunterstützungsvorrichtung zur Unterstützung der Befahrung enger Fahrwege
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20160000816A1
(en)
|
2013-04-05 |
2016-01-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
WO2014170383A1
(en)
|
2013-04-18 |
2014-10-23 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
KR20220079690A
(ko)
|
2014-04-01 |
2022-06-13 |
베링거잉겔하임베트메디카게엠베하 |
말과 동물에서 대사 장애의 치료
|
WO2017064193A1
(en)
|
2015-10-15 |
2017-04-20 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|